Semaglutide‐Induced Weight Loss Does Not Impair Muscle Function and Improves Endurance Running Capacity in Obese Mice

ABSTRACT Background Semaglutide, a member of the glucagon‐like peptide‐1 receptor agonists, induces substantial weight loss, primarily through appetite suppression and reduced energy intake. In addition to fat mass reduction, a considerable loss of lean body mass is also observed. How these effects compare to conventional caloric restriction is unclear. The aim of the current study was to compare the effects of semaglutide injections and energy‐matched caloric restriction on skeletal muscle mass, function and exercise capacity. Methods An 8‐month‐old high‐fat diet‐induced obese male C57BL/6J mice were pair‐fed ( n = 14), with one receiving semaglutide injections (SEMA; 30 μg/kg/day) and the other undergoing energy‐matched caloric restriction (CR; sham PBS injections) for 28 days. A group of obese mice ( n = 12) continued unrestricted high‐fat feeding and served as controls (CON). Body mass and energy intake were monitored daily. During the final week, exercise capacity was assessed using a progressive treadmill test with oxygen consumption and lactate measurements. At study completion, mice were euthanized, and slow‐ and fast‐twitch muscles (soleus [SOL] and extensor digitorum longus [EDL]) were dissected, weighed and used for ex vivo assessment of mechanical and contractile properties. Results Despite similar energy intake, SEMA mice lost more body mass than CR mice (20.9 ± 4.9 vs. 14.8% ± 5.8%, p < 0.01). Both groups exhibited lower SOL muscle mass compared with CON (10.0 ± 0.7 mg; SEMA: 9.1 ± 0.8 mg, p < 0.01; CR: 9.4 ± 0.7 mg, p < 0.05), whereas EDL muscle mass was not significantly different. During the treadmill test, SEMA mice displayed higher relative VO 2 peak (43.4 ± 3.0 mL/min/ kg 0.75 ) compared with CR (40.8 ± 2.6 mL/min/kg 0.75 , p < 0.05) and CON (38.6 ± 2.69 mL/min/kg 0.75 , p < 0.001), together with advantages in running distance and maximal running speed, which were largely attributable to lower body mass. SOL and EDL force, normalized to muscle mass and PCSA, did not differ between groups (SOL: 21.2 ± 2.8 N/g and 22.4 ± 3.1 N/cm 2 [SEMA], 20.8 ± 2.4 N/g and 21.7 ± 2.5 N/cm 2 [CR], 19.7 ± 3.5 N/g and 20.4 ± 3.7 N/cm 2 [CON]; EDL: 22.8 ± 2.2 N/g and 17.0 ± 2.0 N/cm 2 [SEMA], 24.5 ± 2.5 N/g and 18.2 ± 2.0 N/cm 2 [CR], 22.9 ± 2.1 N/g and 16.8 ± 1.8 N/cm 2 [CON]). Muscle contraction and relaxation kinetics as well as stretched induced hysteresis and relaxation were similar across groups. Conclusions In obese mice, semaglutide induces greater weight loss but similar muscle loss than energy‐matched caloric restriction, while improving aerobic endurance without compromising skeletal muscle function.

Authors

Institutions

Publication Details

Journal
Journal of Cachexia Sarcopenia and Muscle
Published
2026-11-17
DOI
https://doi.org/10.1002/jcsm.70427
Primary Topic
Muscle Physiology and Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Semaglutide‐Induced Weight Loss Does Not Impair Muscle Function and Improves Endurance Running Capacity in Obese Mice

Leonardo Cesanelli, Petras Minderis, Aivaras Ratkevičius, Tomas Venckūnas et al.
6 links
Journal of Cachexia Sarcopenia and Muscle
Muscle Physiology and Disorders
article

Semaglutide‐Induced Weight Loss Does Not Impair Muscle Function and Improves Endurance Running Capacity in Obese Mice

Leonardo Cesanelli, Petras Minderis, Aivaras Ratkevičius, Tomas Venckūnas, Mažvydas Sviderskis, Stuart R. Gray
article en

Abstract

ABSTRACT Background Semaglutide, a member of the glucagon‐like peptide‐1 receptor agonists, induces substantial weight loss, primarily through appetite suppression and reduced energy intake. In addition to fat mass reduction, a considerable loss of lean body mass is also observed. How these effects compare to conventional caloric restriction is unclear. The aim of the current study was to compare the effects of semaglutide injections and energy‐matched caloric restriction on skeletal muscle mass, function and exercise capacity. Methods An 8‐month‐old high‐fat diet‐induced obese male C57BL/6J mice were pair‐fed ( n = 14), with one receiving semaglutide injections (SEMA; 30 μg/kg/day) and the other undergoing energy‐matched caloric restriction (CR; sham PBS injections) for 28 days. A group of obese mice ( n = 12) continued unrestricted high‐fat feeding and served as controls (CON). Body mass and energy intake were monitored daily. During the final week, exercise capacity was assessed using a progressive treadmill test with oxygen consumption and lactate measurements. At study completion, mice were euthanized, and slow‐ and fast‐twitch muscles (soleus [SOL] and extensor digitorum longus [EDL]) were dissected, weighed and used for ex vivo assessment of mechanical and contractile properties. Results Despite similar energy intake, SEMA mice lost more body mass than CR mice (20.9 ± 4.9 vs. 14.8% ± 5.8%, p < 0.01). Both groups exhibited lower SOL muscle mass compared with CON (10.0 ± 0.7 mg; SEMA: 9.1 ± 0.8 mg, p < 0.01; CR: 9.4 ± 0.7 mg, p < 0.05), whereas EDL muscle mass was not significantly different. During the treadmill test, SEMA mice displayed higher relative VO 2 peak (43.4 ± 3.0 mL/min/ kg 0.75 ) compared with CR (40.8 ± 2.6 mL/min/kg 0.75 , p < 0.05) and CON (38.6 ± 2.69 mL/min/kg 0.75 , p < 0.001), together with advantages in running distance and maximal running speed, which were largely attributable to lower body mass. SOL and EDL force, normalized to muscle mass and PCSA, did not differ between groups (SOL: 21.2 ± 2.8 N/g and 22.4 ± 3.1 N/cm 2 [SEMA], 20.8 ± 2.4 N/g and 21.7 ± 2.5 N/cm 2 [CR], 19.7 ± 3.5 N/g and 20.4 ± 3.7 N/cm 2 [CON]; EDL: 22.8 ± 2.2 N/g and 17.0 ± 2.0 N/cm 2 [SEMA], 24.5 ± 2.5 N/g and 18.2 ± 2.0 N/cm 2 [CR], 22.9 ± 2.1 N/g and 16.8 ± 1.8 N/cm 2 [CON]). Muscle contraction and relaxation kinetics as well as stretched induced hysteresis and relaxation were similar across groups. Conclusions In obese mice, semaglutide induces greater weight loss but similar muscle loss than energy‐matched caloric restriction, while improving aerobic endurance without compromising skeletal muscle function.

Journal of Cachexia Sarcopenia and MuscleVol. 17(6)
Lithuanian Sports University (LT), Queen Mary University of London (GB), William Harvey Research Institute (GB), University of Glasgow (GB)
Lietuvos Mokslo Taryba
Good health and well-being
Muscle Physiology and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon